2020
Recalcitrant methicillin-resistant Staphylococcus aureus infection of bone cells: Intracellular penetration and control strategies
Yu K, Song L, Kang HP, Kwon HK, Back J, Lee FY. Recalcitrant methicillin-resistant Staphylococcus aureus infection of bone cells: Intracellular penetration and control strategies. Bone And Joint Research 2020, 9: 49-59. PMID: 32435455, PMCID: PMC7229311, DOI: 10.1302/2046-3758.92.bjr-2019-0131.r1.Peer-Reviewed Original ResearchMethicillin-resistant Staphylococcus aureus (MRSA) infectionsEarly antibiotic administrationHours of injuryStandard of careStaphylococcus aureus infectionBone resident cellsEffect of cefazolinBone Joint ResAntibiotic regimensAntibiotic administrationCombined administrationAntibiotic treatmentAureus infectionProtective effectSurgical preparationMRSA growthOpen fracturesPreparation agentsDetergent susceptibilityPrimary murine osteoblastsBacterial bioburdenMRSAColony formationRifampicinBone cells
2014
Systemic Therapy in Patients with Resectable and Unresectable Cases of Giant Cell Tumor: A Systematic Review
Kaiser P, Compton J, Caldwell J, Hickernell T, Lee F. Systemic Therapy in Patients with Resectable and Unresectable Cases of Giant Cell Tumor: A Systematic Review. Journal Of Cancer Therapy 2014, 2014: 339-353. DOI: 10.4236/jct.2014.54041.Peer-Reviewed Original ResearchGiant cell tumorAnti-osteoclastic agentsSystemic bisphosphonatesSystemic treatmentResectable tumorsUnresectable casesRecurrence rateCell tumorsSide effectsCases of GCTMetastatic giant cell tumorUnresectable giant cell tumorPrimary giant cell tumorSevere side effect profileStabilization of diseaseOverall recurrence rateRetrospective case seriesSide effect profileSubset of patientsHigh-level evidenceSeries of patientsLow recurrence ratePrimary bone tumorsStandard of careCommon benign tumor